Cambridge Heart To Exhibit At Sudden Cardiac Arrest Association 2009 Annual Meeting October 9th-11th

Main Category: Heart Disease
Also Included In: Cardiovascular / Cardiology
Article Date: 09 Oct 2009 - 5:00 PDT

email to a friend   printer friendly   view / write opinions

Cambridge Heart, Inc. (OTCBB-CAMH) will participate in the Sudden Cardiac Arrest Association's 2nd Annual Meeting and Medical Education Conference in Chicago, Illinois October 9th through the 11th, to showcase their Microvolt T-Wave AlternansTM (MTWA) technology designed to identify patients at risk for Sudden Cardiac Arrest (SCA). The exhibit will feature the HearTwave® II, Cambridge Heart's flagship diagnostic system capable of performing both stress and MTWA testing.

The Sudden Cardiac Arrest Association (SCAA) is the largest advocacy organization in the U.S. exclusively dedicated to SCA. The 2009 Annual Meeting brings together survivors, patients, physicians, nurses, emergency professionals, and other community advocates working to broaden public awareness, improve emergency response, and increase access to preventive medical care - all with the goal of saving lives from sudden cardiac arrest.

"Our annual meeting coincides with Sudden Cardiac Arrest Awareness Month and SCAA values the support of Cambridge Heart as we work to raise public understanding about cardiac arrest risk factors and treatment options," said Chris Chiames, Executive Director of SCAA.

"SCA is the leading cause of death in the United States and can affect anyone," said Ali Haghighi-Mood, Cambridge Heart President and CEO. Our support of this important organization will help to increase awareness of the dangers of SCA and to educate on the importance of prediction and prevention."

Cambridge Heart manufactures the HearTwave® II which incorporates its patented MTWA technology into a state-of-the-art stress system. MTWA is a tool that can be used to help identify and manage SCA risk for many patients including those with myocardial infarction (MI), heart failure, cardiomyopathy or syncope. Additional information on the product and the benefits of MTWA testing are available at http://www.CambridgeHeart.com

Source
Cambridge Heart, Inc.